Literature DB >> 19826755

Long-term control of clival chordoma with initial aggressive surgical resection and gamma knife radiosurgery for recurrence.

Eiji Ito1, Kiyoshi Saito, Takeshi Okada, Tetsuya Nagatani, Tetsuro Nagasaka.   

Abstract

PURPOSE: Chordomas are locally destructive tumors with high rates of recurrence, and therapeutic strategies remain controversial. This study analyzed long-term outcomes for clival chordomas after initial aggressive surgical resection and gamma knife radiosurgery for recurrence and investigated clinical factors predicting recurrence.
METHODS: Clinical records were reviewed for 19 consecutive patients (11 men, 8 women; mean age, 43.1 years) with clival chordoma who underwent initial surgical resection using skull base approaches (mean follow-up after surgical resection, 87.2 months). All tumors were aggressively removed, along with the surrounding bone. Four patients were treated with radiotherapy after surgical resection.Recurrent lesions were treated with gamma knife radio surgery or reoperation. Factors predicting tumor recurrence were analyzed, including age, tumor extension, extent of resection and MIB-1 labeling index. Patient status was evaluated using the Karnofsky performance scale (KPS).
RESULTS: Tumor resection was total, subtotal and partial in 14, 4 and 1 patients, respectively. Tumors recurred in 11 patients. Overall, 2- and 5-year progression-free survival rates were 77.9% and 47.9%, respectively. The MIB-1 labeling index was independently associated with recurrence.The optimum cutoff point for the MIB-1 labeling index was 3.44%. All recurrent tumors were totally resected or controlled by gamma knife (mean follow-up after recurrence, 71.2 months). All patients survived and were active (mean KPS at final follow-up, 89.5%).
CONCLUSION: Long-term control of clival chordomas was achieved. Recurrent tumors were controlled with gamma knife radiosurgery, since lesions were localized and small after initial aggressive resection. The MIB-1 labeling index can provide important information for predicting tumor recurrence.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19826755     DOI: 10.1007/s00701-009-0535-7

Source DB:  PubMed          Journal:  Acta Neurochir (Wien)        ISSN: 0001-6268            Impact factor:   2.216


  19 in total

1.  Classification and surgical approaches for transnasal endoscopic skull base chordoma resection: a 6-year experience with 161 cases.

Authors:  Songbai Gui; Xuyi Zong; Xinsheng Wang; Chuzhong Li; Peng Zhao; Lei Cao; Yazhuo Zhang
Journal:  Neurosurg Rev       Date:  2016-02-03       Impact factor: 3.042

2.  Salvage Therapy for Local Progression following Definitive Therapy for Skull Base Chordomas: Is There a Role of Stereotactic Radiosurgery?

Authors:  Linton T Evans; Franco DeMonte; David R Grosshans; Amol J Ghia; Ahmed Habib; Shaan M Raza
Journal:  J Neurol Surg B Skull Base       Date:  2019-02-21

3.  OUTCOME OF CLIVAL CHORDOMAS AFTER SKULL BASE SURGERIES WITH MEAN FOLLOW-UP OF 10 YEARS.

Authors:  Takamitsu Tamura; Taku Sato; Yugo Kishida; Masahiro Ichikawa; Keiko Oda; Eiji Ito; Tadashi Watanabe; Jun Sakuma; Kiyoshi Saito
Journal:  Fukushima J Med Sci       Date:  2015-09-11

4.  Treatment and Outcome of Patients with Skull Base Chordoma: A Meta-analysis.

Authors:  Moran Amit; Shorook Na'ara; Yoav Binenbaum; Salem Billan; Gil Sviri; Jacob T Cohen; Ziv Gil
Journal:  J Neurol Surg B Skull Base       Date:  2014-05-27

Review 5.  The biological basis for modern treatment of chordoma.

Authors:  Roberto Jose Diaz; Michael D Cusimano
Journal:  J Neurooncol       Date:  2011-03-08       Impact factor: 4.130

6.  Image-guided, intensity-modulated radiation therapy (IG-IMRT) for skull base chordoma and chondrosarcoma: preliminary outcomes.

Authors:  Arjun Sahgal; Michael W Chan; Eshetu G Atenafu; Laurence Masson-Cote; Gaurav Bahl; Eugene Yu; Barbara-Ann Millar; Caroline Chung; Charles Catton; Brian O'Sullivan; Jonathan C Irish; Ralph Gilbert; Gelareh Zadeh; Michael Cusimano; Fred Gentili; Normand J Laperriere
Journal:  Neuro Oncol       Date:  2014-12-27       Impact factor: 12.300

7.  Fascin expression in skull base chordoma: correlation with tumor recurrence and dura erosion.

Authors:  Ziyun Gao; Qiuhang Zhang; Feng Kong; Ge Chen; Mingchu Li; Hongchuan Guo; Jiantao Liang; Yuhai Bao; Feng Ling
Journal:  Med Oncol       Date:  2012-02-16       Impact factor: 3.064

8.  Adjuvant Stereotactic Radiosurgery and Radiation Therapy for the Treatment of Intracranial Chordomas.

Authors:  Winward Choy; Sergei Terterov; Nolan Ung; Tania Kaprealian; Andy Trang; Antonio DeSalles; Lawrance K Chung; Neil Martin; Michael Selch; Marvin Bergsneider; William Yong; Isaac Yang
Journal:  J Neurol Surg B Skull Base       Date:  2015-08-03

9.  Association of surgical resection and survival in patients with malignant primary osseous spinal neoplasms from the Surveillance, Epidemiology, and End Results (SEER) database.

Authors:  Debraj Mukherjee; Kaisorn L Chaichana; Scott L Parker; Ziya L Gokaslan; Matthew J McGirt
Journal:  Eur Spine J       Date:  2012-12-21       Impact factor: 3.134

10.  Peri-operative prognostic factors for primary skull base chordomas: results from a single-center cohort.

Authors:  Emanuele La Corte; Morgan Broggi; Alberto Raggi; Silvia Schiavolin; Francesco Acerbi; Giovanni Danesi; Mariangela Farinotti; Giovanni Felisati; Alberto Maccari; Bianca Pollo; Marco Saini; Claudia Toppo; Francesca Valvo; Riccardo Ghidoni; Maria Grazia Bruzzone; Francesco DiMeco; Paolo Ferroli
Journal:  Acta Neurochir (Wien)       Date:  2020-01-16       Impact factor: 2.216

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.